Skip to main content

Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer.

Publication ,  Journal Article
Jones, J; Ciombor, K; Wu, C; Bekaii-Saab, T; Strickler, J
Published in: Oncology (Williston Park, N.Y.)
October 2021

Metastatic colorectal cancer (mCRC) is the second most common cause of cancer-related death worldwide. In the mid-1980s, the median overall survival (OS) for patients with mCRC ranged from 10 to 12 months from the time of initial diagnosis. In more recent studies, this median has more than doubled and is commonly reported at more than 25 to 30 months. These improvements are due, in large part, to the introduction of multiple novel agents during the last 3 decades. Despite these improvements, however, nearly all patients treated with palliative chemotherapy will eventually develop resistance and ultimately succumb to progression of metastatic disease. Understanding the mechanisms by which malignant cells evade treatment could unlock novel therapeutic strategies that overcome resistance and improve survival. In this review, we will discuss some of the drivers of therapeutic resistance in patients with mCRC and present some novel strategies to overcome resistance.

Duke Scholars

Published In

Oncology (Williston Park, N.Y.)

DOI

ISSN

0890-9091

Publication Date

October 2021

Volume

35

Issue

10

Start / End Page

654 / 660

Related Subject Headings

  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Proto-Oncogene Proteins p21(ras)
  • Proto-Oncogene Proteins B-raf
  • Neoplasm Metastasis
  • Molecular Targeted Therapy
  • Humans
  • ErbB Receptors
  • Drug Resistance, Neoplasm
  • Colorectal Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jones, J., Ciombor, K., Wu, C., Bekaii-Saab, T., & Strickler, J. (2021). Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer. Oncology (Williston Park, N.Y.), 35(10), 654–660. https://doi.org/10.46883/onc.2021.3510.0654
Jones, Jeremy, Kristen Ciombor, Christina Wu, Tanios Bekaii-Saab, and John Strickler. “Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer.Oncology (Williston Park, N.Y.) 35, no. 10 (October 2021): 654–60. https://doi.org/10.46883/onc.2021.3510.0654.
Jones J, Ciombor K, Wu C, Bekaii-Saab T, Strickler J. Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer. Oncology (Williston Park, NY). 2021 Oct;35(10):654–60.
Jones, Jeremy, et al. “Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer.Oncology (Williston Park, N.Y.), vol. 35, no. 10, Oct. 2021, pp. 654–60. Epmc, doi:10.46883/onc.2021.3510.0654.
Jones J, Ciombor K, Wu C, Bekaii-Saab T, Strickler J. Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer. Oncology (Williston Park, NY). 2021 Oct;35(10):654–660.

Published In

Oncology (Williston Park, N.Y.)

DOI

ISSN

0890-9091

Publication Date

October 2021

Volume

35

Issue

10

Start / End Page

654 / 660

Related Subject Headings

  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Proto-Oncogene Proteins p21(ras)
  • Proto-Oncogene Proteins B-raf
  • Neoplasm Metastasis
  • Molecular Targeted Therapy
  • Humans
  • ErbB Receptors
  • Drug Resistance, Neoplasm
  • Colorectal Neoplasms